Managing atypical hemolytic uremic syndrome: chapter 2.
Kidney Int
; 87(5): 882-4, 2015 May.
Article
en En
| MEDLINE
| ID: mdl-25951068
ABSTRACT
Licht et al. present the 2-year follow-up data of the landmark trials studying the efficacy of eculizumab in the treatment of atypical hemolytic uremic syndrome (aHUS). They report sustained improvements in hematologic parameters, continued safety, and additional improvements in kidney function with extended treatment. This report adds a layer of comfort to our care of patients with this rare disease; however, it is unlikely to be the final chapter in the treatment of aHUS.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Anticuerpos Monoclonales Humanizados
/
Síndrome Hemolítico Urémico Atípico
Límite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Kidney Int
Año:
2015
Tipo del documento:
Article
País de afiliación:
Estados Unidos